B. Riley Starts Perspective Therapeutics With Buy Rating, $1.20 Price Target; Says Well-Positioned to Break Out of Biotech Pack
B. Riley Starts Perspective Therapeutics With Buy Rating, $1.20 Price Target; Says Well-Positioned to Break Out of Biotech Pack
B. Riley以买入评级启动Perspective Therapeutics,目标股价为1.20美元;表示完全有能力突破生物技术组合
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册